Skip to content
Previous
Next

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.

About Biosimilars

As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.

Resources

Learn more about biosimilars and their benefits for patients and healthcare systems.

Latest news

The case for an Ontario biosimilar switching policy

The Government of Ontario spending $3 million more than it needs to on biologic drugs every single week. Biosimilars are the solution, writes Biosimilars Canada President Jim Keon in his op-ed for QP Briefing.

Read more

Biosimilars Canada Encourages Stakeholders to Join #GlobalBiosimilarsWeek

Toronto – November 1, 2021 – Biosimilars Canada, in collaboration with the International Generic and Biosimilar Medicines Association (IGBA), invites biosimilars stakeholders to take part in the second annual Global Biosimilars Week from November 1 to 5. This social media awareness campaign will...
Read more

Alberta adds NovoRapid insulin aspart to biosimilar switching program

Effective October 1, 2021, adult patients who take NovoRapid insulin aspart will be required to switch to a biosimilar version by April 1, 2022. All new patient starts for insulin aspart will be covered for a biosimilar.

Read more